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Abstract 
Historically, our understanding of the cytotoxicity of radiation has centred on 
tumour cell-autonomous mechanisms of cell death. Here, tumour cell death 
occurs when a threshold number of radiation-induced non-reparable double-
stranded DNA breaks is exceeded. However, in recent years, the importance of 
immune mechanisms of cell death has been increasingly recognised, as well as 
the impact of radiotherapy on non-malignant cellular components of the tumour 
microenvironment. Conserved anti-viral pathways that detect foreign nucleic 
acid in the cytosol and drive downstream interferon responses via the 
cGAS/STING pathway are key components of the immune response to 
radiation-induced DNA damage. In pre-clinical models, acute induction of a type 
1 interferon response is important for both direct and abscopal tumour 
responses to radiation. Inhibitors of the DNA damage response show promise in 
augmenting this inflammatory interferon response. However, a substantial 
proportion of tumours show chronic interferon signalling prior to radiotherapy 
which paradoxically drives immunosuppression. This chronic interferon 
signalling leads to treatment resistance, and heterotypic interactions between 
stromal fibroblasts and tumour cells contribute to an aggressive tumour 
phenotype. The effect of radiotherapy on myeloid cell populations, particularly 
tumour-associated macrophages, has an additional impact on the immune 
tumour microenvironment. It is not yet clear how the above pre-clinical findings 
translate into a human context. Human tumours show greater intra-tumoural 
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genomic heterogeneity and more variable levels of chromosomal instability than 
experimental murine models. High quality translational studies of immunological 
changes occurring during radiotherapy that incorporate intrinsic tumour biology 
will enable a better understanding of the immunological consequences of 
radiation-induced DNA damage in patients.     
 
Key words: radiation-induced DNA damage response, interferon response, 
abscopal response, stromal fibroblasts, macrophages 
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Introduction 
Patients who are systemically immunosuppressed, either pathologically or 
iatrogenically, can show inferior responses to radiotherapy [1]. In addition, loco-
regionally delivered radiotherapy can trigger tumour responses outside the 
radiation field which are, at least in part, immunologically-mediated [2]. These 
observations suggest an important link between clinical responses to 
radiotherapy and the immune system. Until recently, it was widely believed that 
the cytotoxicity of radiotherapy was entirely tumour cell-autonomous and 
mediated by radiation-induced DNA damage (RIDD). According to this model, 
inflicting breaks in nuclear DNA above an unspecified threshold that the cell is 
incapable of repairing would lead to cell death, typically via apoptosis or mitotic 
catastrophe [3]. Latterly, non-tumour cell-autonomous, immunological aspects 
of radiation-induced cell death have been seen as increasingly important, 
alongside a greater understanding of the profound effects of radiotherapy on the 
wider tumour microenvironment.  
Radiotherapy has both immunostimulatory and immunosuppressive effects [4]. 
The balance between these two effects depends on the intrinsic biology of 
individual tumours and their associated microenvironments, as well as the 
physical characteristics of the delivered radiation. A central component of this 
balance is the relationship between the RIDD response and the subsequent 
immune reaction. Radiotherapy can induce immunogenic cell death, 
characterised by tumour cell surface expression of calreticulin and release of 
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danger-associated molecular patterns (DAMPs), including ATP and high-
mobility group protein B1 [5]. Conserved anti-viral pathways that detect foreign 
nucleic acid in the cytosol and drive downstream interferon responses are key 
components of the immune response to radiotherapy. This review will discuss 
our current understanding of the immunological consequences of RIDD, with 
particular focus on the role of conserved interferon responses. Whilst the review 
focuses on RIDD, the immunological consequences of DNA damage that we 
describe are of relevance beyond radiotherapy. We will also discuss some of 
the key effects of radiotherapy on components of the tumour microenvironment. 
 
RIDD can drive production of type 1 interferon and a subsequent anti-
tumour CD8+ T cell response 
Pre-clinical work has demonstrated that the efficacy of radiotherapy in 
immunocompetent melanoma murine models relies upon induction of type 1 
interferons, which stimulate both innate and adaptive anti-tumour immune 
responses [6]. Ablative radiotherapy increased intra-tumoural interferon-β and 
the therapeutic efficacy of radiotherapy was abrogated in mice lacking the 
IFNα/β receptor 1. Tumour-infiltrating CD45+ haematopoietic cells 
(predominantly dendritic cells) were the main source of the type 1 interferon. 
Subsequent tumour rejection required CD8+ T cells, and the associated 
expansion of antigen-specific CD8+ T cells was driven by interferon-β.   
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Further work has shown that the acute induction of type 1 interferon following 
radiotherapy is predominantly driven by cytosolic double-stranded DNA 
(dsDNA) that arises as a consequence of RIDD [7]. Cytosolic dsDNA is 
“sensed” by the cyclic guanosine monophosphate–adenosine monophosphate 
synthase (cGAS), which increases levels of the downstream adaptor stimulator 
of interferon genes (STING). STING drives increased production of type 1 
interferon which leads to activation of BATF3+ dendritic cells and subsequent 
priming of tumour-specific CD8+ T cells [6, 7] as shown in Figure 1.  
Whilst antigen-presenting cells, such as conventional dendritic cells, are likely to 
be the main source of type 1 interferon, intrinsic cancer cell production has also 
been demonstrated [8]. In vitro irradiation of TSA1 and 4T1 mouse breast 
cancer cells and MCA38 mouse colorectal cancer cells, in the absence of 
stroma, showed that generation of interferon-stimulated gene products can be a 
tumour cell-autonomous response independent of antigen-presenting cells. In 
addition, delivery of cytosolic DNA from irradiated tumour cells to antigen-
presenting cells via exosomes has also been recently reported [9]. This study 
specifically identified dsDNA within the exosome, as opposed to dsDNA on its 
external surface, as the key factor inducing downstream interferon production. 
Furthermore, exosomes derived from tumours treated with radiotherapy were 
able to induce protective anti-tumour immunity when injected subcutaneously as 
a vaccination strategy. This immune response included induction of tumour-
specific T cells, demonstrating the potent immunogenicity of such exosomes.  
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Micronuclei arising from cell cycle progression through mitosis in cells 
harbouring double-strand breaks, for example following radiotherapy, can also 
drive acute production of type 1 interferons via the cGAS/STING pathway [10]. 
This alternative mechanism of acute interferon production was elucidated by 
identification of a biphasic DNA damage-induced inflammatory response in 
irradiated cells. This included a delayed-onset response occurring days after 
DNA damage, alongside the rapid response occurring within minutes to hours 
discussed earlier. In irradiated MCF1A cells, and following disruption of the 
micronuclear envelope, cGAS localised to micronuclei post-mitosis. Robust 
activation of interferon-stimulated genes (e.g. STAT1) followed, although this 
effect was lost if mitotic progression was blocked, or if cGAS or STING were 
knocked down. An independent set of experiments validated the above 
mechanism: at 6 days after irradiation at 10Gy, an enhanced green fluorescent 
protein (eGFP) reporter driven by the IFNβ1 promoter showed increased activity 
specifically in cells with micronuclei [10].  
Both cytosolic dsDNA and micronuclear DNA are likely to be important in driving 
acute interferon production and the subsequent anti-tumour inflammatory 
response following radiation. A substantial body of evidence from 
immunocompetent murine models indicates that the combination of 
radiotherapy plus immune checkpoint blockade (ICB) with anti-CTLA4 [11], anti-
PD-1 [12], or both [13], can enhance both direct and abscopal responses to 
radiotherapy. Acute induction of the STING pathway is of particular importance 
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for the abscopal response and both tumour-intrinsic and exosomal-mediated 
mechanisms of acute interferon production are likely to contribute to this effect 
(Figure 1). 
Recent work has shed light on important associations between the presence of 
micronuclei and chromosomal instability in the form of chromothripsis [14]. 
However, the precise mechanism of cell death in cells with micronuclei remains 
unclear and is likely to have important immunological consequences beyond the 
interferon responses discussed above. Apoptotic cell death, mitotic catastrophe 
or a combination of both may occur in irradiated cells with micronuclei [15]. 
Historically, apoptosis has been considered to have predominantly anti-
inflammatory consequences. More recently, the phagocytic clearance of 
apoptotic cells by efferocytosis has been shown to increase 
immunosuppressive cytokines and leukocytes [16]. However, these anti-
inflammatory effects are likely to be counterbalanced by the highly pro-
inflammatory pre-apoptotic fragmentation and sensing of dsDNA [17].   
 
Optimising acute induction of type 1 interferons in a therapeutic context 
Optimising fraction size and total dose of radiotherapy 
Optimal acute induction of type 1 interferons is dependent on both the fraction 
size and the total dose of radiation [11]. In a series of experiments using TSA1 
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and MCA38 breast and colorectal mouse tumour models respectively, the 
combination of radiotherapy, dosed at 24 Gy in 3 fractions or 30 Gy in 5 
fractions, plus CTLA4 blockade, yielded anti-tumour responses in both the 
directly-irradiated tumour and a second non-irradiated tumour on the 
contralateral flank (i.e. an abscopal response). However, the abscopal response 
was lost when a single ablative dose of 20 Gy was applied in combination with 
CTLA4 blockade.   
The mechanistic basis of such radiation dose-dependent abscopal responses 
centres on induction of the cytoplasmic DNA exonuclease, Trex1, which 
degrades cytosolic dsDNA. Activation of Trex1 is thought to occur when supra-
threshold levels of cytosolic dsDNA are reached [8]. In the above murine 
models, a short-lived but substantial induction of Trex1 was seen after a single 
20 Gy fraction, but not after the other fractionation schedules, and this dose-
schedule was associated with attenuation of the type 1 interferon response. The 
additional relevance of total dose of radiation was also shown experimentally; 
here, 24 Gy in 3 fractions generated much stronger abscopal responses than 8 
Gy in a single fraction [8]. As yet, these intriguing preclinical findings on fraction 
size and total dose await human validation. Nevertheless, a large number of 
translational clinical trials, encompassing different fraction sizes and ICB, are 
underway, which should help address this question [18]. 
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Addition of DNA damage response inhibitors (DDRi) to enhance the 
immunogenicity of radiation 
Addition of specific DNA damage response inhibitors (DDRi) to radiotherapy 
may increase cytosolic DNA and thereby augment the interferon responses 
described above. AZD6738 is an ATR inhibitor (ATRi) that has shown 
radiosensitising effects preclinically [19]. It is currently being evaluated in early 
phase clinical trials, including the PATRIOT study (NCT02223923), which 
includes an arm in which AZD6738 is combined with palliative radiation [20]. 
AZD6738 has been evaluated in combination with radiotherapy in mouse 
models of K-ras mutant cancer. Here, the ATRi reduced radiation-induced 
surface expression of PD-L1 on tumour cells and also significantly reduced 
tumour infiltration of regulatory T cells. Enhanced anti-tumour CD8+ activity was 
seen as a result of these effects [21].  
Further evaluation of AZD6738 in an immunocompetent mouse model of HPV-
driven malignancy also showed that AZD6738 potentiated radiation-induced 
inflammatory changes in the tumour microenvironment [22]. An increase in 
pattern recognition receptors sensing cytoplasmic nucleic acid and interferon-
stimulated genes was seen with addition of ATRi to radiotherapy, compared to 
radiotherapy alone. Further transcript-level data indicated increased antigen 
processing and presentation with ATRi plus radiotherapy versus radiotherapy 
alone. The combination of radiotherapy and ATRi also enhanced the 
intratumoural myeloid cell infiltrate. Although this myeloid infiltrate included a 
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mixture of immunostimulatory and immunosuppressive cell populations, this 
study indicates the therapeutic potential of combining radiotherapy with DDRi 
and established or novel immunomodulatory agents.  
The above data indicate considerable potential for DDRi, particularly ATRi, plus 
radiation to augment the type 1 interferon response to radiation. It will be 
exciting to see whether other DDRi, for example PARP inhibitors, increase 
quantities of cytosolic DNA and thereby augment the downstream interferon 
response.  
 
Novel immunomodulatory agents in combination with radiotherapy 
Blockade of Chemokine Receptor Type 2 (CCR2) represents an exciting 
example of a novel immunomodulatory strategy used alongside ablative 
radiotherapy [23]. CCR2 is a receptor for Monocyte Chemoattractant Proteins 1, 
3 and 5 (CCL2, CCL7 and CCL12, respectively) and is expressed on the 
surface of a subset of monocytic myeloid-derived suppressor cells (mMDSCs). 
These CCR2+Ly6Chi mMDSC cells are important mediators of radioresistance 
via immunosuppressive effects, which include negative regulation of tumour-
specific CD8+ T cell responses [24]. Liang et al. demonstrated that the murine 
anti-CCR2 monoclonal antibody MC-21, plus stereotactic radiotherapy given at 
a dose of 20 Gy, significantly improved tumour rejection and substantially 
increased the CD8+/CD4+FoxP3+ (Treg) ratio in MC38 colorectal and Lewis 
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lung cancer murine models [24]. Tumour rejection was augmented with further 
addition of the STING agonist cGAMP to anti-CCR2 and ablative RT. 
Intriguingly, the above study also showed that innate DNA sensing via STING, 
and the subsequent type 1 interferon response discussed earlier, play a key 
role in the recruitment of mMDSCs. This demonstrates the complexities of type 
1 interferon signalling in tumour immunology, as well as how induction of STING 
can be a double-edged sword with opposing anti-tumour and pro-tumour 
immunological consequences. 
 
The differential effects of acute versus chronic interferon signalling. 
Acute induction of type 1 interferon to drive activation of dendritic cells and 
subsequent CD8+ T cell priming is central to the generation of anti-tumour 
immune responses. However, chronic interferon signalling present within 
tumours prior to any treatment can promote an entirely different tumour 
phenotype, in which interferon paradoxically has a predominantly 
immunosuppressive effect [25] (Figure 2). Benci et al. explored the mechanisms 
of PD-L1-independent resistance to radiotherapy plus anti-CTLA4 in murine 
melanoma models. Here, chronic type I and II interferon production led to a 
multitude of STAT1-driven epigenetic and transcriptomic modifications [25]. The 
consequences of such modifications included induction of multiple T cell 
inhibitor receptor (TCIR) ligands, including PD-L1, TNFRSF14, LGALS9, MHCII 
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and CD86, as well as T cell exhaustion. Inhibition of interferon signalling by 
knockout of IFNA, IFNGR or STAT1, or use of the JAK1/2 inhibitor Ruxolitinib, 
plus dual ICB inhibition, led to expansion and re-invigoration of distinct 
populations of exhausted T cells. The specific population showing most 
expansion was PD-1highTCIRhighT cells, which also showed an increase in 
markers of improved function including Ki67 and Granzyme B [25]. 
Both of the interferon stimultated genes (ISGs), IFIT1 and Mx1, showed a tight 
association with increased STAT1 expression. To demonstrate the clinical 
relevance of chronic interferon signalling, the expression of both genes was 
analysed in a recently published cohort of melanoma patients receiving PD-1 
inhibition [25]. The computational modelling strategy incorporated ISG 
expression and the rates of non-synonymous single nucleotide variations 
(nsSNV), to account for the known effect of varying neo-antigen load. The key 
findings were that lower IFIT1 and Mx1 expression and higher rates of nsSNV 
correlated with increased response to treatment with anti-PD-1.  
The precise relevance of such chronic interferon signalling to 
radioresponsiveness is not entirely clear. A substantial body of evidence 
indicates that upregulation of ISGs in tumours predicts a radioresistant 
phenotype. An experimentally-derived interferon-related DNA damage 
resistance signature (IRDS), including STAT1, ISG15 and IFIT1, was developed 
by repeated irradiation to a xenograft of the radiosensitive cell line SCC-61 to 
generate a radioresistant tumour [26]. The resulting ISG-enriched signature [27] 
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has subsequently been evaluated in different in vitro cell systems and xenograft 
models. Upregulation of IRDS genes has consistently been demonstrated 
during fractionated radiotherapy [28, 29] and constitutive expression of STAT1 
and other ISGs has repeatedly predicted radioresistance [30]. In patients, 
analysis of gene expression databases has shown constitutive expression of 
ISGs in a substantial proportion of patients with head and neck, prostate, 
breast, lung and cervical cancers and high grade gliomas [31-34]. In breast 
cancer, an IRDS-based 7-gene classifier, including STAT1, was evaluated in 
295 patients treated with adjuvant radiotherapy [27]. Patients with high 
expression of the signature (IRDS+) showed a significantly greater rate of loco-
regional failure at ten years post-radiotherapy.   
Collectively, these studies indicate that constitutive STAT1/interferon signalling 
drives aggressive and radioresistant tumour phenotypes. Measurement of ISGs, 
such as Mx1 and IFIT1, may help identify such phenotypes [25]. It is clear that 
the impact of chronic interferon signalling in driving unfavourable tumour biology 
is substantial (Figure 2). However, it is much less clear how tumours driven by 
chronic immunosuppressive interferon production can be manipulated to enable 
the beneficial anti-tumour effects of acute interferon induction during 
radiotherapy to predominate.   
 
The role of stromal fibroblasts in chronic interferon signalling 
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A multi-faceted heterotypic interaction between cancer-associated fibroblasts 
(CAFs) and tumour cells has been elucidated in recent years (Figure 3). This 
complex interaction provides a mechanistic explanation for some of the 
aggressive tumour behaviour associated with upregulation of ISGs discussed 
above. A key aspect of the heterotypic interaction is the exosomal transfer of 
double-stranded RNA (dsRNA) from CAFs to tumour cells, where it binds the 
pattern recognition receptor retinoic acid-inducible gene-I-like receptor (RIG-I) 
and drives production of ISGs [35]. Intriguingly, the specific dsRNA acting as a 
DAMP within exosomes has recently been identified as the long non-coding 
RNA, RN7SL1 [36]. RN7SL1 exists endogenously in the cytosol, yet it is 
upregulated and unshielded in exosomes by an extensive transcriptional 
program in CAFs, including NOTCH1 and MYC pathway signalling. 
If breast cancer cells are separated from CAFs by a transwell filter, which 
enables exosomal transfer but does not permit cell-to-cell contact, upregulation 
of tumour cell ISGs is seen, but the radioresistance observed in ISG-high 
tumours does not occur [35]. This lack of radio-resistance, despite paracrine 
signalling via exosomal dsRNA as described above, can be explained by further 
juxtacrine signalling in which NOTCH3 in breast cancer cells binds JAG1 on 
CAFs via direct cell-to-cell contact. The juxtacrine signalling drives an 
expansion of treatment-resistant CD44+CD24low+ cells with tumour-initiating 
properties. The paracrine and juxtacrine pathways ultimately converge because 
STAT1 enhances the transcriptional response to increased NOTCH3 signalling 
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[35]. The stromal fibroblasts or CAFs, therefore, drive both reduced tumour cell 
death and increased tumour growth.  
Boelens et al. (30) carried out extensive expression profiling of human breast 
tumours as clinical qualification of the mechanisms identified in experimental 
models. Amongst other findings, they showed that breast tumour NOTCH3 and 
stromal JAG1 are important regulators of NOTCH target genes, and that 
NOTCH3 and STAT1 localise to sites of tumour-stroma interaction. Additionally, 
high IRDS/STAT1 and NOTCH3 identify patients with radio- and chemo-
resistance – this gene expression pattern is particularly common in basal and 
claudin-low subtypes of breast cancer, which are known to be enriched when 
cancer stem cell-like features are present. Both NOTCH3 and the IRDS 
(including STAT1) may prove to be useful predictive biomarkers to guide 
treatment with agents that block NOTCH activation, such as gamma secretase 
inhibitors [35].  
 
The importance of myeloid cell populations in the response to 
radiotherapy 
Myeloid populations - for example, tumour-associated macrophages (TAMs) - 
are often abundant in the tumour microenvironment and are an attractive target 
for anticancer therapies, including combinations of radiotherapy and systemic 
agents [37-39].  Macrophages display significant plasticity, but are ordinarily 
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classified between classically-activated (M1) and alternatively-activated 
macrophages (M2). Response to numerous inflammatory stimuli dictates the 
polarisation of macrophages towards M1 or M2 phenotypes [40, 41]. M1 
macrophages are endowed with anti-tumoural activities and act mainly as a 
driver of a protective TH1 immune response, whereas M2 macrophages are 
responsible for tumour growth and resistance to anticancer therapies [42].  
In tumours, macrophages usually possess a deleterious M2 phenotype which 
promotes angiogenesis, suppression of anti-tumour T cell responses, and 
metastatic dissemination. Consequently, high numbers of TAMs are generally 
associated with poor prognosis and lower survival rates in cancer patients [43, 
44]. Several reports have demonstrated an increase in macrophage infiltration 
in tumours following radiotherapy which may limit treatment efficacy. However, 
studies of polarisation of recruited TAMs following radiotherapy have yielded 
conflicting results, depending on the tumour model, radiation fraction size and 
total dose, and the host’s genetic background [45]. 
The RIDD response pathway is likely to be important for the activation of 
macrophages towards a pro-inflammatory M1-like phenotype [46]. Wu et al. 
showed that NOX2-dependent reactive oxygen species (ROS) production 
following radiotherapy induced ATM phosphorylation, which subsequently led to 
IRF5 expression and pro-inflammatory responses in macrophages. These data 
suggest that systemic agents that modulate the RIDD response may favourably 
influence macrophage function to improve anti-tumour responses, as well as 
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enhancing the post-radiotherapy acute type 1 interferon response discussed 
earlier.   
The molecular mechanisms regulating macrophage infiltration and activation 
following radiotherapy in tumours have been extensively investigated. Findings 
indicate that there is potential for therapeutically beneficial immune-modulation 
using agents that may synergise with DDRi. In a xenograft model of non-small 
cell lung carcinoma, interleukin-6 (IL-6) induced the recruitment of macrophages 
in irradiated tumours via CCL2/CCL5 secretion [47]. Colony-stimulating factor-1 
(CSF-1) was also proposed as an important factor in recruiting macrophages in 
mouse mammary tumours [48]. In addition, neutralisation of cytokines that are 
important for M2 polarisation (IL-4 and IL-13) enabled reduction of tumour 
growth. Tumours originating from the 4T1 breast cancer cell line show higher 
proportions of iNOS+ TAMs (M1) following inhibition of matrix metalloproteinase 
14 [49]. M1 macrophage recruitment, together with reduction of anti-
inflammatory TGF-β, improved radiotherapy-mediated tumour control. 
More research is required to understand fully the molecular determinants of 
TAM polarisation following radiotherapy and optimise drug combinations to 
exploit the potential of macrophage reprogramming post-radiotherapy. Possible 
synergistic drug combinations include DDRi in combination with other 
immunomodulatory agents. Such combinations may enable both the 
suppression of deleterious macrophages and the promotion of beneficial anti-
tumour macrophages following radiotherapy. 
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How do immunogenic properties of radiotherapy established in pre-
clinical models apply in a human context? 
Key differences between human tumours and murine model systems 
The mechanistic studies explained above are, by necessity, conducted in 
experimental murine models and it is unclear how these findings translate into a 
human context. The radiotherapy schedules used in the above studies are 
reasonably representative of schedules used in the clinic. However, there are 
important biological differences between primary and secondary human 
tumours and the above model systems. The time period over which branched 
evolution operates within human tumours does not apply to murine models. This 
means that intra-tumoural genomic heterogeneity is likely to be much greater in 
human tumours than in commonly used murine models. Furthermore, the 
biological mechanisms enabling successful metastasis of human tumours do 
not occur in the bilateral flank models typically used to evaluate the abscopal 
response in murine tumour systems. As a consequence, the genetic and 
phenotypic variation between human primary and metastatic tumours is likely to 
be considerably greater than in the equivalent murine models. 
 
Chromosomal instability 
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Human tumours are likely to exhibit a greater degree of chromosomal instability 
(CIN) than their murine equivalents and CIN is thought to occur to a larger 
extent in metastases than in primary tumours [50]. Recent data suggest that 
increased cytosolic DNA and cGAS/STING signalling occur in untreated cancer 
cells with high CIN, and such signalling is involved in metastatic progression. 
Cancer cells with high CIN, and those isolated from metastases, have higher 
numbers of micronuclei and greater quantities of cytosolic DNA than primary 
tumours with low CIN. Additionally, if micronuclear envelope incompetence is 
suppressed, quantities of cytosolic DNA are reduced in high CIN cells. The 
increased cytosolic DNA in high CIN cells can activate non-canonical NFκB 
signalling in a STING-dependent, yet MYC and TBK1-independent, manner. 
Such signalling can be important for metastatic progression, as tumour 
dissemination was reduced in models of high CIN depleted of STING [50]. This 
diversion away from a STING-dependent inflammatory response towards non-
canonical signalling in tumours with high CIN may impact how effectively an 
acute interferon response, and subsequent abscopal response, is generated 
following radiotherapy. 
The DNA exonuclease Trex1, discussed earlier in the context of radiotherapy 
fraction sizes, also has a role in human chromothripsis. Chromothripsis or 
chromosome shattering is thought to occur as a single event during which a 
high number of focal copy number alterations are generated. Trex1 has a 
specific role in the resolution of anaphase bridges following telomere fusion, 
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which is an important mechanism for chromothripsis [51]. This illustrates how 
key proteins linking the DDR and immune response have much wider roles, 
including the regulation of chromosomal stability. The cGAS/STING pathway is 
increasingly recognised to have diverse context-dependent components, and an 
improved understanding of the complexities of this pathway will be necessary 
for the development of successful human trials of immunotherapy/radiation 
combinations. 
 
Generation of anti-tumour CD8+ T cell responses 
Radiation-induced cell lysis causes release of tumour neo-antigens that are 
taken up by antigen presenting cells in the surrounding tumour 
microenvironment. The subsequent sustainment of an anti-tumour immune 
response likely requires generation of CD8+ T memory cells that recognise 
these tumour neo-antigens [52].  A CD8+ T cell response to clonal neo-
antigens, rather than sub-clonal neo-antigens, is thought to be important [53]. 
The considerable genomic diversity of human tumours may limit the 
effectiveness of CD8+ T cell responses following irradiation of a single site, with 
failure to engage neo-antigens that are private to other non-irradiated tumour 
sites. However, it is also possible that ‘epitope spreading’ occurs in which a 
strong response to one epitope supports generation of responses to other less 
immunogenic neo-epitopes [54]. It has been suggested that radiotherapy may 
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increase sub-clonal neoantigens, potentially leading to T cell exhaustion [53]. 
However, to our knowledge this has not been shown to date, in either 
experimental models or patients receiving radiotherapy.  
The evolution of T cell receptor (TCR) clones during radiotherapy, in both 
human and murine models, is a particularly exciting area of current research. In 
a study of radiotherapy combined with CTLA4 blockade in the 4T1 breast 
cancer mouse model, clonally-expanded tumour-specific T cells formed the 
majority of the CD8+ T cell population [55]. Deep sequencing of TCR-β showed 
that radiotherapy broadened the TCR repertoire, as has also been reported in 
other murine tumour models [12, 13]. In contrast, anti-CTLA4 treatment 
increased TCR clonality and, therefore, focussed the TCR repertoire. These 
TCR dynamics, driven by radiation-induced inflammatory changes, may be 
important for the observed tumour rejection in these models.  
Early findings from a human trial of radiotherapy plus ipilimumab in patients with 
non-small cell lung cancer also show a diversification and intensification of TCR 
clones during radiotherapy [56]. In this study, the persistent expansion of 
tumour-specific T cell clones in peripheral blood correlated with partial or 
complete response to treatment. A particularly interesting finding was seen in a 
patient showing a complete response to radiation and ipilimumab. Here, 
expansion of two tumour-specific T cell clones recognising epitopes within the 
gene KPNA2 was seen. KPNA2 is known to be upregulated by radiotherapy. 
Importantly, an increase in serum interferon-β from baseline was significantly 
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correlated with a radiological response to radiotherapy plus ipilimumab. 
Together, these findings suggest that radiation may reveal immunogenic 
mutations by increasing their expression thus enabling antigen presentation, 
production of IFN-β and a subsequent T cell response. These exciting early 
findings require confirmation in other larger patient cohorts together with much 
more research, to understand how radiotherapy plus immunomodulatory 
combinations impact T cell clonal evolution in human tumours.  
 
Conclusion 
There is a wealth of pre-clinical data indicating that RIDD and the immune 
response can be exploited for therapeutic benefit. Radiotherapy and 
immunotherapy as an effective combination has already been demonstrated in 
the randomised placebo-controlled phase III PACIFIC trial of the PD-L1 inhibitor 
durvalumab after chemo-radiotherapy, in locally-advanced lung cancer [57].  
Here, the added overall benefit in terms of median time to death or distant 
metastases of the addition of durvalumab was just over twelve months [58]. 
There is tremendous potential for this substantial survival benefit to be realised 
in other tumour sites, together with further improvements in survival in lung 
cancer. However, there is still a lot that we do not understand about the 
relationship between radiotherapy and the immune response, particularly in a 
human context. Currently, there is an urgent need for high quality human 
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studies with translational endpoints that profile longitudinal changes occurring 
during radiotherapy alone, and with radiation and ICB (or other 
immunomodulatory treatments including chemotherapy) combinations. Such 
studies ideally need to incorporate measures of CIN, stromal fibroblast biology 
and interferon signalling at baseline, and during radiotherapy. These 
translational studies should further our understanding of the evolution of 
tumours, their associated microenvironments and TCR clones during 
radiotherapy, paving the way for therapeutic gains for patients. 
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Figure Legends 
Figure 1. Radiation-induced acute production of type 1 interferon.  
Following tumour cell irradiation, dsDNA is present in the cytosol where it can 
stimulate the dsDNA sensor cGAS and the downstream STING pathway (1). 
Exosomal transfer of dsDNA to antigen presenting cells (APC) can also occur 
leading to cGAS/STING pathway signalling within the APC (2). Micronuclei 
arising in the daughter cells of irradiated tumour cells can also release dsDNA 
which stimulates cGAS and drives signalling via STING (3). Increased signalling 
via the cGAS/STING pathway leads to activation of BATF3+ dendritic cells and 
subsequent priming of tumour-specific T cells. APC: antigen presenting cell; 
dsDNA: double stranded DNA; IFN: interferon; STING, stimulator of interferon 
genes.  
 
Figure 2. Chronic interferon stimulation involving heterotypic interaction 
between tumour cells and cancer-associated fibroblasts. Chronic interferon 
signalling leads to T cell exhaustion via STAT1-driven epigenetic and 
transcriptomic modifications which induce multiple T cell inhibitor receptor 
ligands and lead to T cell exhaustion. Inhibition of interferon signalling by 
knockout of IFNA, IFNGR or STAT1, or use of the JAK1/2 inhibitor ruxolitinib, 
plus dual ICB inhibition, leads to expansion and re-invigoration of exhausted T 
cells. ICB: immune checkpoint blockade; IFNAR: interferon alpha/beta receptor; 
IFNG: interferon-gamma; IFNGR: interferon-gamma receptor; ISGs: interferon-
stimulated genes, MHC: major histocompatibility complex. 
 
Figure 3. The heterotypic interaction between cancer-associated 
fibroblasts and tumour cells contributes to chronic interferon signalling. 
Paracrine signalling involves exosomal transfer of dsRNA from cancer-
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associated fibroblasts to tumour cells, where it binds RIG-I and drives 
production of ISGs. Juxtacrine signalling in which NOTCH3 on tumour cells 
binds JAG1 on CAFs via direct cell-to-cell contact drives expansion of 
radioresistant tumour-initiating cells. dsRNA: double stranded RNA; IRDS: 
interferon-related DNA damage resistance signature; ISG: interferon-stimulated 
genes; NICD: NOTCH intracellular domain; RIG-I: retinoic acid-inducible gene-I-
like receptors. 
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